Cargando…

Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children

Development and guidance of dosing schemes in children have been supported by physiology‐based pharmacokinetic (PBPK) modeling for many years. PBPK models are built on a generic basis, where compound‐ and system‐specific parameters are separated and can be exchanged, allowing the translation of thes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ince, Ibrahim, Dallmann, André, Frechen, Sebastian, Coboeken, Katrin, Niederalt, Christoph, Wendl, Thomas, Block, Michael, Meyer, Michaela, Eissing, Thomas, Burghaus, Rolf, Lippert, Jörg, Willmann, Stefan, Schlender, Jan‐Frederik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361729/ https://www.ncbi.nlm.nih.gov/pubmed/34185905 http://dx.doi.org/10.1002/jcph.1869

Ejemplares similares

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
por: Frechen, Sebastian, et al.
Publicado: (2021)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
por: Schlender, Jan-Frederik, et al.
Publicado: (2018)

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
por: Niederalt, Christoph, et al.
Publicado: (2017)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
por: Willmann, Stefan, et al.
Publicado: (2013)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor
por: Burghaus, Rolf, et al.
Publicado: (2014)

A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
por: Eissing, Thomas, et al.
Publicado: (2011)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
por: Basu, Sumit, et al.
Publicado: (2020)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
por: Britz, Hannah, et al.
Publicado: (2019)

Development of a Physiologically Based Computational Kidney Model to Describe the Renal Excretion of Hydrophilic Agents in Rats
por: Niederalt, Christoph, et al.
Publicado: (2013)

Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance
por: Dickschen, Kristin, et al.
Publicado: (2012)

Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
por: Türk, Denise, et al.
Publicado: (2019)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure
por: Schmitt, Walter, et al.
Publicado: (2021)

Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment
por: Fendt, Rebekka, et al.
Publicado: (2021)

A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
por: Claassen, Karina, et al.
Publicado: (2013)

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
por: Hanke, Nina, et al.
Publicado: (2018)

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
por: Burghaus, Rolf, et al.
Publicado: (2011)

"Bayer" Pflanzenschutz Compendium.
Publicado: (1968)

Bayer's Pharmaceutical Products
Publicado: (1910)

Herbert Bayer : un concepto total.
por: Rodríguez Prampolini, Ida
Publicado: (1975)

Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women
por: Dallmann, André, et al.
Publicado: (2018)

"Bayer 205" in Kala-Azar
por: Megaw, J. W. D.
Publicado: (1923)

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
por: Willmann, Stefan, et al.
Publicado: (2022)

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
por: Vossen, Michaela, et al.
Publicado: (2007)

Acid Mine Drainage Treatment Using Bayer Precipitates Obtained from Seawater Neutralization of Bayer Liquor
por: Kaur, Gurkiran, et al.
Publicado: (2018)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences
por: Lippert, Jörg, et al.
Publicado: (2019)

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
por: Dickschen, Kristin, et al.
Publicado: (2014)

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development
por: Strougo, Ashley, et al.
Publicado: (2012)

Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification
por: Krauss, Markus, et al.
Publicado: (2013)

Green Channel Guiding Denoising on Bayer Image
por: Tan, Xin, et al.
Publicado: (2014)

Three Cases of Plague Treated with 'Bayer 205'
por: Rao, B. R. Ranganatha
Publicado: (1932)

The Failure of "Bayer 205" in the Treatment of Kala-Azar
por: Napier, L. E.
Publicado: (1923)

Four Cases of Plague Treated with 'Bayer 205'
por: Vincent, G. W.
Publicado: (1931)

Eight Cases of Plague Treated with 'Bayer 205'
por: Parulkar, R. D.
Publicado: (1933)

Cannot write session to /tmp/vufind_sessions/sess_88v8dj53ghi387fjn6j1obfn3f